Treatment with apalutamide (Erleada) resulted in a rapid and substantial decline in PSA, and greater magnitude of PSA decline correlated with improvement in several oncologic endpoints, results from the phase III SPARTAN study showed.
A study investigating associations between statin use and prostate cancer outcomes provides further evidence that the medication may have race-related benefit, providing protective effects among Caucasian men but not in African-Americans.
In his latest blog post, Rick Rutherford, CMPE, discusses the effects of recent major changes in the method that Medicare reimburses in-office clinical lab services.
A simple blood test, much like that used to detect tuberculosis, might identify as many as half of bladder cancer patients likely to fail intravesical bacillus Calmette-Guérin immunotherapy.
“This is more evidence that [dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin] is highly effective for patients with bladder cancer,” says researcher Scott M. Gilbert, MD, MS.
Noted in many recent accounts of doctors running for Congress is the fact that, since January 2017, urologists have been fortunate to have one of their own serving in the U.S. House of Representatives—Florida's Neal Dunn, MD.
Studies show moderate alcohol intake has surprising links to prostate disease.
"While these results cannot be extrapolated to men with very high PSA level or advanced clinical stage, the study provides appropriate benchmark data for our contemporary patients with high-risk clinically localized prostate cancer," writes Badar M. Mian, MD.
Selling a bond prior to maturity may require offering a discount, according to Jeff Witz, CFP.
"If a high percentage of the radicals are billed with urethral suspension, then it is likely to be bundled in the future and it is possible that it will be tagged with an indicator that will not allow unbundling," write Ray Painter, MD, and Mark Painter.